KYUSHU UNIVERSITY,NATIONAL UNIVERSITY CORPORATION (Japon)
Inventeur(s)
Kikuchi, Sadato
Nakamura, Shogo
Oizumi, Risa
Konishi, Masayoshi
Higa, Mitsuru
Taniguchi, Ikuo
Abrégé
Provided are a calcium carbonate generation method and a system that make it possible to use calcium-containing waste to generate high-purity calcium carbonate.?According to the present invention, a calcium carbonate generation method that generates calcium carbonate from calcium-containing waste is characterized by having a calcium dissolution step for adding aqueous hydrochloric acid to the calcium-containing waste to dissolve the calcium and generate an aqueous solution that includes calcium ions, a separation step for adjusting a hydrogen ion concentration index for the aqueous solution that includes the calcium ions and separating a component that includes at least one substance selected from the group that consists of Si, Al, Mg, and heavy metals from the aqueous solution, and a calcium carbonate recovery step for using the aqueous solution obtained via the separation step and an aqueous solution that includes potassium carbonate and/or sodium carbonate to generate calcium carbonate.
KYUSHU UNIVERSITY, NATIONAL UNIVERSITY CORPORATION (Japon)
SUMITOMO METAL MINING CO., LTD. (Japon)
Inventeur(s)
Sasaki, Keiko
Konadu, Kojo Twum
Mendoza Flores, Diego Moizes
Sakai, Ryotaro
Suyama, Ikumi
Hirajima, Tsuyoshi
Aoki, Yuji
Murase, Nana
Abrégé
Provided is a method of pretreating gold ore that allows easily recovering gold and a gold recovery method in which a recovery proportion of gold is high even when the gold ore contains sulfide or a carbonaceous component. The pretreatment method includes a biological oxidation step of bringing the gold ore containing the sulfide into contact with iron oxidizing bacteria and holding them for a predetermined time. The gold recovery method includes: a pretreatment step of pretreating the gold ore by the pretreatment method; a leaching step of leaching the gold from the gold ore to obtain a leaching solution; an adsorption step of adsorbing gold in the leaching solution to activated carbon; and an eluting step of eluting the gold from the activated carbon to obtain a gold solution. Since the sulfide confining the gold particles is oxidatively decomposed by an action of the iron oxidizing bacteria, the gold particles are liberated, thus facilitating the recovery of the gold. As a result, the recovery proportion of the gold can be high.
C22B 1/00 - Traitement préliminaire de minerais ou de débris ou déchets métalliques
C22B 3/04 - Extraction de composés métalliques par voie humide à partir de minerais ou de concentrés par lixiviation
C22B 3/18 - Extraction de composés métalliques par voie humide à partir de minerais ou de concentrés à l'aide de micro-organismes ou d'enzymes, p.ex. de bactéries ou d'algues
C22B 3/24 - Traitement ou purification de solutions, p.ex. de solutions obtenues par lixiviation par des procédés physiques, p.ex. par filtration, par des moyens magnétiques par adsorption sur des substances solides, p.ex. par extraction avec des résines solides
KYUSHU UNIVERSITY, NATIONAL UNIVERSITY CORPORATION (Japon)
Inventeur(s)
Yamato, Kenta
Miyata, Takeshi
Kusakabe, Takahiro
Lee, Jae Man
Masuda, Akitsu
Abrégé
[Problem] To provide: a method for simply producing an immunogenic chrysalis for oral administration; and a chrysalis which is for oral administration and produced by said method. [Solution] This method for producing a chrysalis for oral use comprises a step for infecting a larva or chrysalis of a baculovirus infectious insect with a recombinant baculovirus, into which DNA encoding an antigen protein has been introduced, and freeze-drying a chrysalis pupated from the infected larva or the infected chrysalis.
A01K 67/033 - NÉCESSITÉS COURANTES DE LA VIE ÉLEVAGE; CHASSE; PIÉGEAGE; PÊCHE ÉLEVAGE; AVICULTURE; APICULTURE; PISCICULTURE; PÊCHE; OBTENTION D'ANIMAUX, NON PRÉVUE AILLEURS; NOUVELLES RACES D'ANIMAUX Élevage ou obtention d'animaux, non prévus ailleurs; Nouvelles races d'animaux Élevage ou obtention d'invertébrés; Nouvelles races d'invertébrés
A23L 33/10 - Modification de la qualité nutritive des aliments; Produits diététiques; Leur préparation ou leur traitement en utilisant des additifs
A61K 35/12 - Substances provenant de mammifères; Compositions comprenant des tissus ou des cellules non spécifiés; Compositions comprenant des cellules souches non embryonnaires; Cellules génétiquement modifiées
A61K 39/00 - Préparations médicinales contenant des antigènes ou des anticorps
KYUSHU UNIVERSITY, NATIONAL UNIVERSITY CORPORATION (Japon)
Inventeur(s)
Utsunomiya, Tomoaki
Sato, Iku
Tanaka, Kouji
Shinkawa, Yasuhiro
Sakai, Kenta
Abrégé
[Problem] To safely and efficiently raise a floating body for a spar-type offshore wind power generation facility by injecting ballast water, at sea. [Solution] A method for raising a floating body 4 for a spar-type offshore wind power generation facility, which is floating sideways, by injecting ballast water at sea, the method comprising: a first step for bringing the floating body 4 for the spar-type offshore wind power generation facility into a state in which the position of center of gravity is made eccentric by a center-of-gravity decentering means; and a second step for raising the floating body 4 for the spar-type offshore wind power generation facility upright by injecting ballast water. The center-of-gravity decentering means can be a weight 2 attached to an outer surface of the floating body 4, or solid ballast 34 put in the floating body 4.
B63B 35/00 - Embarcations ou structures flottantes similaires spécialement adaptées à des finalités spécifiques et non prévues ailleurs
F03D 13/25 - Dispositions pour monter ou supporter des mécanismes moteurs à vent; Pylônes ou tours pour des mécanismes moteurs à vent spécialement adaptés à l’installation offshore
B63B 77/10 - Transport ou installation de structures en mer sur site par flottaison, p.ex. en utilisant des barges semi-submersibles, en ballastant la structure ou transport de plateformes pétrolières-gazières spécialement adaptés aux installations de production d'énergie électrique, p.ex. aux éoliennes ou aux générateurs à turbine marémotrice
5.
COMPOUNDS HAVING INHIBITORY EFFECT ON MITOCHONDRIAL HYPERFISSION
KYUSHU UNIVERSITY, NATIONAL UNIVERSITY CORPORATION (Japon)
Inventeur(s)
Kawanishi, Eiji
Ojida, Akio
Nishida, Motohiro
Kato, Yuri
Abrégé
The present invention provides a compound for treating or preventing diseases caused by excessive mitochondrial divisions. The present invention relates to a compound represented by formula (1) (in the formula: R1 and R1' are each independently hydrogen, optionally substituted lower alkyl, optionally substituted lower cycloalkyl, or the like; R2 is optionally substituted lower alkyl, optionally substituted lower cycloalkyl, or the like; R3 and R4 are each independently hydrogen, halogen, hydroxy, nitro, cyano, optionally substituted lower alkyl or the like; R5 and R6 are each independently optionally substituted lower alkyl, optionally substituted lower cycloalkyl, or the like; X is nitrogen or oxygen; Y is carbon, nitrogen, or oxygen; and the broken line represents the presence or absence of a bond), a pharmaceutically acceptable salt or solvate thereof, or a prodrug thereof.
A61K 31/4745 - Quinoléines; Isoquinoléines condensées en ortho ou en péri avec des systèmes hétérocycliques condensées avec des systèmes cycliques ayant l'azote comme hétéro-atome d'un cycle, p.ex. phénanthrolines
A61P 1/04 - Médicaments pour le traitement des troubles du tractus alimentaire ou de l'appareil digestif des ulcères, des gastrites ou des œsophagites par reflux, p.ex. antiacides, antisécrétoires, protecteurs de la muqueuse
A61P 3/10 - Médicaments pour le traitement des troubles du métabolisme de l'homéostase du glucose de l'hyperglycémie, p.ex. antidiabétiques
A61P 9/04 - Agents inotropes, c. à d. stimulants de la contraction cardiaque; Médicaments pour le traitement de l'insuffisance cardiaque
A61P 21/00 - Médicaments pour le traitement des troubles du système musculaire ou neuromusculaire
A61P 43/00 - Médicaments pour des utilisations spécifiques, non prévus dans les groupes
C07D 211/90 - Atomes de carbone comportant trois liaisons à des hétéro-atomes avec au plus une liaison à un halogène
MEMBRANE PROTEIN ANALYSIS SUBSTRATE, METHOD OF PRODUCING MEMBRANE PROTEIN ANALYSIS SUBSTRATE, METHOD OF ANALYZING MEMBRANE PROTEIN AND MEMBRANE PROTEIN ANALYSIS GRID
KYUSHU UNIVERSITY, NATIONAL UNIVERSITY CORPORATION (Japon)
Inventeur(s)
Shimada, Atsushi
Abrégé
This membrane protein analysis substrate comprises: an electron microscope grid having a plurality of through holes; a lipid bilayer membrane provided covering at least one of the plurality of through holes; and a membrane protein retained in a portion of the lipid bilayer membrane overlapping in a planar manner with the through holes. The lipid bilayer membrane comprises a lipid monolayer; and the lipid monolayer is larger than the through holes in plan view, adheres to the grid, and constitutes a part of the lipid bilayer membrane.
G01N 33/68 - Analyse chimique de matériau biologique, p.ex. de sang ou d'urine; Test par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligands; Test immunologique faisant intervenir des protéines, peptides ou amino-acides
H01J 37/20 - Moyens de support ou de mise en position de l'objet ou du matériau; Moyens de réglage de diaphragmes ou de lentilles associées au support
7.
IONIC LIQUID, SOLVENT, PREPARATION, AND TRANSDERMALLY ABSORBABLE AGENT
KYUSHU UNIVERSITY, NATIONAL UNIVERSITY CORPORATION (Japon)
Inventeur(s)
Goto, Masahiro
Abrégé
An ionic liquid has a structure represented by the following general formula (1). In the general formula (1), R represents a substituted or unsubstituted alkyl group or a substituted or unsubstituted alkenyl group, and at least one ethylene group comprising the alkenyl group may be substituted with a vinylene group. X+ represents a phospholipid with a cationic group.
KYUSHU UNIVERSITY, NATIONAL UNIVERSITY CORPORATION (Japon)
Inventeur(s)
Yamada, Kenichi
Kuninobu, Kenichiro
Abrégé
Provided is a compound that achieves a good balance between the LO scavenging ability and the LOO* scavenging ability. The compound of die present invention or a salt thereof is represented 5 by the following formula (1):In the formula (1), R1 and R2 may be the same or different and are each independently a hydrogen atom or an alkyl group, R3 is -OR4 or -NHR5, R4 is a sec-butyl group, a tert-butyl group, or an iso¬ butyl group, and R5 is a sec-butyl group, a tert-butyl group, or an iso-butyl group. Compounds of the invention can be used as cell protectant agents, cell growth-promoting agents, or the like.
C07C 229/36 - Composés contenant des groupes amino et carboxyle liés au même squelette carboné ayant des groupes amino et carboxyle liés à des atomes de carbone acycliques du même squelette carboné le squelette carboné contenant des cycles aromatiques à six chaînons avec au moins un groupe amino et un groupe carboxyle liés au même atome de carbone du squelette carboné
A61K 31/216 - Esters, p.ex. nitroglycérine, sélénocyanates d'acides carboxyliques d'acides ayant des cycles aromatiques, p.ex. bénactizyne, clofibrate
KYUSHU UNIVERSITY, NATIONAL UNIVERSITY CORPORATION (Japon)
SUMITOMO METAL MINING CO., LTD. (Japon)
Inventeur(s)
Hirajima, Tsuyoshi
Miki, Hajime
Sasaki, Keiko
Suyantara, Gde Pandhe Wisnu
Semoto, Yuki
Kuroiwa, Shigeto
Aoki, Yuji
Tanaka, Yoshiyuki
Abrégé
Provided is an ore dressing method that can efficiently separate copper ore from molybdenum ore. The ore dressing method comprises a conditioning step for adding a disulfite to ore slurry comprising copper ore and molybdenum ore; and, after the conditioning step, an ore flotation step in which ore flotation is performed using the ore slurry. By selectively increasing the hydrophilicity of the copper ore with the disulfite, a difference in hydrophilicity between the copper ore and molybdenum ore can be established. As a result, a selective flotation of the molybdenum ore can be brought about and the copper ore can be efficiently separated from the molybdenum ore.
KYUSHU UNIVERSITY, NATIONAL UNIVERSITY CORPORATION (Japon)
SOMAR CORPORATION (Japon)
Inventeur(s)
Ise, Hirohiko
Matsuo, Saori
Abrégé
This O-GlcNAcylated protein-like substance contains at least one unit selected from the group consisting of an N-acetylglucosamine unit, carboxy group-containing radical polymerizable units, a styrene unit, a polyethyleneimine unit, a poly-L-lysine unit, and a biotin unit. This fibrosis therapeutic drug contains the O-GlcNAcylated protein-like substance.
KYUSHU UNIVERSITY, NATIONAL UNIVERSITY CORPORATION (Japon)
Inventeur(s)
Tsutsui, Hiroyuki
Ide, Tomomi
Ohtani, Kisho
Matsushima, Shoji
Ikeda, Masataka
Abrégé
The present invention provides a pharmaceutical for the prevention and/or treatment of nonischemic cardiomyopathy, said pharmaceutical containing dendritic cells obtained via a method including: a step in which mononuclear cells are cultured in the presence of GM-CSF and IL-2; and a step in which the cultured cells are pulsed with a-Galactosylceramide.
KYUSHU UNIVERSITY, NATIONAL UNIVERSITY CORPORATION (Japon)
Inventeur(s)
Yagi, Yusuke
Nakamura, Takahiro
Abrégé
Provided is a high-performance PPR protein. This PPR protein has more motifs that are linked together than the conventional 7 to 14 motifs and binds to a long base sequence. The PPR motifs are represented by: (A-1) PPR motif comprising a sequence of SEQ ID NO: 9 or 401; (C-1) PPR motif comprising a sequence of SEQ ID NO: 10; (G-1) PPR motif comprising a sequence of SEQ ID NO: 11; and (U-1) PPR motif comprising a sequence of SEQ ID NO:12. These motifs are useful as PPR motifs for, in the order given, adenine, cytosine, guanine, and uracil within a target base sequence.
C12N 15/10 - Procédés pour l'isolement, la préparation ou la purification d'ADN ou d'ARN
C12N 15/11 - Fragments d'ADN ou d'ARN; Leurs formes modifiées
C12N 15/29 - Gènes codant pour des protéines végétales, p.ex. thaumatine
C12N 15/63 - Introduction de matériel génétique étranger utilisant des vecteurs; Vecteurs; Utilisation d'hôtes pour ceux-ci; Régulation de l'expression
C12Q 1/68 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismes; Compositions à cet effet; Procédés pour préparer ces compositions faisant intervenir des acides nucléiques
13.
PPR PROTEIN CAUSING LESS AGGREGATION AND USE OF THE SAME
KYUSHU UNIVERSITY, NATIONAL UNIVERSITY CORPORATION (Japon)
Inventeur(s)
Yagi, Yusuke
Imai, Takayoshi
Tamai, Takayuki
Nakamura, Takahiro
Teramoto, Takamasa
Abrégé
In order to improve the agglomerating property of PPR protein, A6 amino acid of the first PPR motif (M1) from the N terminus is configured to be more hydrophilic. Further, A9 amino acid of M1 is configured to be a hydrophilic amino acid or glycine. A6 amino acid is preferably asparagine or aspartic acid, and A9 amino acid is preferably glutamine, glutamic acid, lysine, or glycine. Proteins including such PPR motifs as M1 motif have not only an improved agglomerating property but also can have high affinity to a target nucleic acid.
C07K 14/00 - Peptides ayant plus de 20 amino-acides; Gastrines; Somatostatines; Mélanotropines; Leurs dérivés
C07K 7/06 - Peptides linéaires ne contenant que des liaisons peptidiques normales ayant de 5 à 11 amino-acides
C07K 7/08 - Peptides linéaires ne contenant que des liaisons peptidiques normales ayant de 12 à 20 amino-acides
C07K 14/46 - Peptides ayant plus de 20 amino-acides; Gastrines; Somatostatines; Mélanotropines; Leurs dérivés provenant d'humains provenant de vertébrés
C12N 1/15 - Champignons; Leurs milieux de culture modifiés par l'introduction de matériel génétique étranger
C12N 1/19 - Levures; Leurs milieux de culture modifiés par l'introduction de matériel génétique étranger
C12N 1/21 - Bactéries; Leurs milieux de culture modifiés par l'introduction de matériel génétique étranger
C12N 5/10 - Cellules modifiées par l'introduction de matériel génétique étranger, p.ex. cellules transformées par des virus
C12N 15/10 - Procédés pour l'isolement, la préparation ou la purification d'ADN ou d'ARN
C12N 15/12 - Gènes codant pour des protéines animales
C12N 15/63 - Introduction de matériel génétique étranger utilisant des vecteurs; Vecteurs; Utilisation d'hôtes pour ceux-ci; Régulation de l'expression
C12Q 1/68 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismes; Compositions à cet effet; Procédés pour préparer ces compositions faisant intervenir des acides nucléiques
KYUSHU UNIVERSITY, NATIONAL UNIVERSITY CORPORATION (Japon)
Inventeur(s)
Suzuki, Atsushi
Kawamata, Masaki
Abrégé
A method for producing cells that have been genome edited at a single allele. The method includes a step for introducing (A) and (B) into cells. (A) (a1) Guide RNA to which at least one nucleotide residue has been added at the 5' end of a spacer sequence, (a2) guide RNA that includes a spacer sequence that is mismatched to a target sequence at one or more bases, and/or (a3) an expression vector that causes the guide RNA of (a1) or (a2) to be expressed. (B) The Cas9 protein and/or an expression vector that causes the Cas9 protein to be expressed.
C12N 15/63 - Introduction de matériel génétique étranger utilisant des vecteurs; Vecteurs; Utilisation d'hôtes pour ceux-ci; Régulation de l'expression
C12Q 1/02 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismes; Compositions à cet effet; Procédés pour préparer ces compositions faisant intervenir des micro-organismes viables
C12Q 1/68 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismes; Compositions à cet effet; Procédés pour préparer ces compositions faisant intervenir des acides nucléiques
KYUSHU UNIVERSITY, NATIONAL UNIVERSITY CORPORATION (Japon)
Inventeur(s)
Fukui, Yoshinori
Uruno, Takehito
Kanai, Motomu
Oisaki, Kounosuke
Tsutsumi, Ryosuke
Abrégé
Provided is a compound that is usable as an active ingredient of an anticancer agent. Preferably, provided is a compound that has a DOCK1-inhibiting activity and exerts an anticancer effect based on the activity. A compound represented by formula (A) or a salt thereof: in formula (A), X represents a carbon atom or a nitrogen atom; Y represents an oxygen atom, a hydroxy group or a hydrocarbon group; R1 and R2 are different and represent a hydrogen atom or a group represented by formula (A-1): (in formula (A-1), R6 represents a pyrrolidino group or a phenyl group, and n2 represents 0 or 1) ; R3 represents -CO-R7 (wherein R7 represents an alkoxy group, an alkyl group or an alkylamino group), a 1,3-oxazole group, an alkylhydroxy group, a hydrogen atom or an oxygen atom; R4 represents a hydrogen atom, an oxygen atom or a hydrocarbon group in which a hydrogen atom may be substituted; R5 represents a halogen atom, a halogenated alkyl group or a halogenated alkylthio group; and n1 represents an integer of 0-5.) ; in formula (A), a solid line on the skeleton of the compound represents a single bond, a double line consisting of a solid line and a dotted line represents a single or double bond, and tow dotted lines represent a non-bond or a double bond.
C07D 401/12 - Composés hétérocycliques contenant plusieurs hétérocycles comportant des atomes d'azote comme uniques hétéro-atomes du cycle, au moins un cycle étant un cycle à six chaînons avec un unique atome d'azote contenant deux hétérocycles liés par une chaîne contenant des hétéro-atomes comme chaînons
A61K 31/40 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p.ex. guanéthidine ou rifamycines ayant des cycles à cinq chaînons avec un azote comme seul hétéro-atome d'un cycle, p.ex. sulpiride, succinimide, tolmétine, buflomédil
A61K 31/437 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p.ex. guanéthidine ou rifamycines ayant des cycles à six chaînons avec un azote comme seul hétéro-atome d'un cycle condensés en ortho ou en péri avec des systèmes hétérocycliques le système hétérocyclique contenant un cycle à cinq chaînons ayant l'azote comme hétéro-atome du cycle, p.ex. indolizine, bêta-carboline
A61K 31/4439 - Pyridines non condensées; Leurs dérivés hydrogénés contenant d'autres systèmes hétérocycliques contenant un cycle à cinq chaînons avec l'azote comme hétéro-atome du cycle, p.ex. oméprazole
A61K 31/444 - Pyridines non condensées; Leurs dérivés hydrogénés contenant d'autres systèmes hétérocycliques contenant un cycle à six chaînons avec l'azote comme hétéro-atome du cycle, p.ex. amrinone
A61K 31/4545 - Pipéridines non condensées, p.ex. pipérocaïne contenant d'autres systèmes hétérocycliques contenant un cycle à six chaînons avec l'azote comme hétéro-atome du cycle, p.ex. pipampérone, anabasine
A61K 31/4709 - Quinoléines non condensées contenant d'autres hétérocycles
A61K 31/58 - Composés contenant des systèmes cycliques du cyclopenta[a]hydrophénanthrène; Leurs dérivés, p.ex. stéroïdes contenant des hétérocycles, p.ex. danazol, stanozolol, pancuronium ou digitogénine
C07D 233/76 - Deux atomes d'oxygène, p.ex. hydantoïne avec des radicaux hydrocarbonés substitués liés au troisième atome de carbone du cycle
C07D 401/14 - Composés hétérocycliques contenant plusieurs hétérocycles comportant des atomes d'azote comme uniques hétéro-atomes du cycle, au moins un cycle étant un cycle à six chaînons avec un unique atome d'azote contenant au moins trois hétérocycles
C07D 405/04 - Composés hétérocycliques contenant à la fois un ou plusieurs hétérocycles comportant des atomes d'oxygène comme uniques hétéro-atomes du cycle et un ou plusieurs hétérocycles comportant des atomes d'azote comme uniques hétéro-atomes du cycle contenant deux hétérocycles liés par une liaison directe de chaînon cyclique à chaînon cyclique
C07D 413/04 - Composés hétérocycliques contenant plusieurs hétérocycles, au moins un cycle comportant des atomes d'azote et d'oxygène comme uniques hétéro-atomes du cycle contenant deux hétérocycles liés par une liaison directe de chaînon cyclique à chaînon cyclique
C07D 417/12 - Composés hétérocycliques contenant plusieurs hétérocycles, au moins un cycle comportant des atomes de soufre et d'azote comme uniques hétéro-atomes du cycle, non prévus par le groupe contenant deux hétérocycles liés par une chaîne contenant des hétéro-atomes comme chaînons
KYUSHU UNIVERSITY, NATIONAL UNIVERSITY CORPORATION (Japon)
KURUME RESEARCH PARK CO., LTD. (Japon)
Inventeur(s)
Ninomiya, Toshiharu
Katakura, Yoshinori
Kuhara, Satoru
Hata, Jun
Fujita, Kazuhiro
Abrégé
A disease risk assessment apparatus (100) includes an assessment unit (1) for assessing the risk of developing dementia in a subject, based on the concentration of an amino acid in the blood of the subject. The amino acid includes at least one selected from the group consisting of histidine, phenylalanine, leucine, isoleucine, methionine, threonine, glycine, glutamine, lysine, asparagine, homocysteine, cystathionine, S-adenosylmethionine, and S-adenosylhomocysteine.
G16H 50/30 - TIC spécialement adaptées au diagnostic médical, à la simulation médicale ou à l’extraction de données médicales; TIC spécialement adaptées à la détection, au suivi ou à la modélisation d’épidémies ou de pandémies pour l’évaluation des risques pour la santé d’une personne
A61P 25/00 - Médicaments pour le traitement des troubles du système nerveux
A61P 25/28 - Médicaments pour le traitement des troubles du système nerveux des troubles dégénératifs du système nerveux central, p.ex. agents nootropes, activateurs de la cognition, médicaments pour traiter la maladie d'Alzheimer ou d'autres formes de démence
KYUSHU UNIVERSITY, NATIONAL UNIVERSITY CORPORATION (Japon)
SUMITOMO METAL MINING CO., LTD. (Japon)
Inventeur(s)
Hirajima, Tsuyoshi
Miki, Hajime
Gde, Pandhe Wisnu Suyantara
Imaizumi, Yuji
Aoki, Yuji
Takida, Eri
Abrégé
Provided is an ore dressing method capable of efficiently separating copper ore from molybdenum ore. The ore dressing method is provided with: a conditioning step for adding a sulfite as a surface treatment agent to an ore slurry comprising copper ore and molybdenum ore; and after the conditioning step, an ore flotation step for performing ore flotation using the ore slurry. By selectively increasing the hydrophilicity of the copper ore with the sulfite, it is possible to impart a difference in hydrophilicity between the copper ore and the molybdenum ore. As a result, it is possible to selectively cause the molybdenum ore to float and to separate the copper ore from the molybdenum ore efficiently.
KYUSHU UNIVERSITY, NATIONAL UNIVERSITY CORPORATION (Japon)
Inventeur(s)
Nakamura, Takahiro
Yagi, Yusuke
Abrégé
[Problem] The present invention addresses the problem of developing a method for controlling a target RNA. [Solution] Provided is a fusion protein containing: a functional domain that improves the protein expression from mRNA; and a PPR protein capable of selectively binding RNA bases or specifically binding an RNA base sequence, with respect to a target mRNA.
KYUSHU UNIVERSITY, NATIONAL UNIVERSITY CORPORATION (Japon)
Inventeur(s)
Imai, Toshiyasu
Kawasaki, Toru
Ogawa, Toru
Inoue, Kazuhide
Abrégé
A medicine for preventing and/or treating multiple sclerosis, particularly pain such as neuropathic pain associated with multiple sclerosis and the like, said medicine containing, as an active ingredient, a compound having an antagonistic activity on P2X4 receptors, e.g., a compound represented by general formula (IH), or a salt of the compound, or a hydrate or solvate of the compound or the salt.
A61P 21/00 - Médicaments pour le traitement des troubles du système musculaire ou neuromusculaire
A61P 25/28 - Médicaments pour le traitement des troubles du système nerveux des troubles dégénératifs du système nerveux central, p.ex. agents nootropes, activateurs de la cognition, médicaments pour traiter la maladie d'Alzheimer ou d'autres formes de démence
20.
CULTURE METHOD FOR DIFFERENTIATING PRIMORDIAL GERM CELLS INTO FUNCTIONALLY MATURE OOCYTES
NATIONAL AGRICULTURE AND FOOD RESEARCH ORGANIZATION (Japon)
KYUSHU UNIVERSITY, NATIONAL UNIVERSITY CORPORATION (Japon)
Inventeur(s)
Obata, Yayoi
Hirao, Yuji
Hayashi, Katsuhiko
Abrégé
The present invention addresses the problem of providing a method for differentiating primordial germ cells into functionally mature GV stage oocytes by in vitro culture. The present invention pertains to a method for differentiating primordial germ cells into functional GV stage oocytes in vitro including (a) a step for forming secondary follicles by culturing primordial germ cells and feeder cells adjacent to the primordial germ cells under conditions that eliminate the effects of estrogen or factors having a similar function to estrogen, (b) a step for partially cleaving the bonds between the granulosa cell layer and the thecal cell layer among the oocyte, granulosa cell layer, and thecal cell layer that constitute the formed secondary follicles, and (c) a step for differentiating the oocytes into functional GV stage oocytes by culturing the oocytes and granulosa cell layer that constitute the secondary follicles and the thecal cell layer in medium including a polymer compound.
KYUSHU UNIVERSITY, NATIONAL UNIVERSITY CORPORATION (Japon)
SUMITOMO METAL MINING CO., LTD. (Japon)
Inventeur(s)
Goto, Masahiro
Kubota, Fukiko
Abrégé
Provided is a system for efficiently recovering trace metal from a large amount of a raw material, such as when trace metal is recovered from nickel oxide ore. This ion exchange resin has, on a carrier, an amide derivative represented by the following general formula. In the formula, R1 and R2 represent the same or different alkyl groups, R3 represents a hydrogen atom or an alkyl group, and R1 represents a hydrogen atom or an arbitrary group, other than an amino group, bonded to a carbon as an amino acid. The amide derivative is preferably a glycineamide derivative. The carrier preferebly includes a primary amine and/or a secondary amino.
B01J 45/00 - Echange d'ions dans lequel se forme un complexe ou un chélate; Utilisation d'une substance comme échangeur d'ions formant des complexes ou des chélates; Traitement d'une substance en vue d'améliorer ses propriétés d'échange d'ions formant des complexes ou des chélates
B01J 20/22 - Compositions absorbantes ou adsorbantes solides ou compositions facilitant la filtration; Absorbants ou adsorbants pour la chromatographie; Procédés pour leur préparation, régénération ou réactivation contenant une substance organique
C22B 3/06 - Extraction de composés métalliques par voie humide à partir de minerais ou de concentrés par lixiviation dans des solutions inorganiques acides
C22B 3/42 - Traitement ou purification de solutions, p.ex. de solutions obtenues par lixiviation par extraction utilisant l'échange d'ions
22.
DIAZEPINEDIONE DERIVATIVES AND COMPOSITIONS THEREOF USEFUL AS P2X4 RECEPTOR ANTAGONIST
The present invention relates to a compound represented by general formula (II) having a P2X4 receptor antagonist action. (II) (In the formula, R1a to R6a are a hydrogen atom, an alkyl group having 1 to 8 carbon atoms, etc., Xa is C or N, and Ya is N or C (=O), provided that when Xa is C, Ya is N, and when Xa is N, Ya is C (=O), a dual line consisting of solid and broken lines is a single bond or a double bond, Aa is a benzene ring, a pyridine ring, etc., Da is a tetrazole ring, an imidazole ring, etc., Ea is -(CR9aR10a)p-Ta-, and Ga is a benzene ring, a pyridine ring, etc.)
C07D 403/10 - Composés hétérocycliques contenant plusieurs hétérocycles, comportant des atomes d'azote comme uniques hétéro-atomes du cycle, non prévus par le groupe contenant deux hétérocycles liés par une chaîne carbonée contenant des cycles aromatiques
A61K 31/551 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p.ex. guanéthidine ou rifamycines ayant des cycles à sept chaînons, p.ex. azélastine, pentylènetétrazole ayant deux atomes d'azote comme hétéro-atomes d'un cycle, p.ex. clozapine, dilazèpe
A61P 43/00 - Médicaments pour des utilisations spécifiques, non prévus dans les groupes
C07D 401/04 - Composés hétérocycliques contenant plusieurs hétérocycles comportant des atomes d'azote comme uniques hétéro-atomes du cycle, au moins un cycle étant un cycle à six chaînons avec un unique atome d'azote contenant deux hétérocycles liés par une liaison directe de chaînon cyclique à chaînon cyclique
C07D 403/08 - Composés hétérocycliques contenant plusieurs hétérocycles, comportant des atomes d'azote comme uniques hétéro-atomes du cycle, non prévus par le groupe contenant deux hétérocycles liés par une chaîne carbonée contenant des cycles alicycliques
23.
DIAZEPINYL DERIVATIVES AND COMPOSITIONS THEROF USEFUL AS P2X4 RECEPTOR ANTAGONIST
The present invention relates to a compound represented by general formula (I) having a P2X4 receptor antagonist action. (I) (In the formula, R1, R2 and R3 are a hydrogen atom, an alkyl group having 1 to 8 carbon atoms, an alkoxy group having 1 to 8 carbon atoms, a halogen atom, etc., X is C or N, and Y is N or C (=O), provided that when X is C, Y is N, and when X is N, Y is C (=O), a dual line consisting of solid and broken lines is a single bond or a double bond, n is an integer of 0 to 6, Z is O, S or a bond, and A is a benzene ring, a pyridine ring, etc.)
C07D 243/10 - Composés hétérocycliques contenant des cycles à sept chaînons comportant deux atomes d'azote comme uniques hétéro-atomes du cycle les atomes d'azote étant en positions 1, 4 condensés avec des carbocycles ou avec des systèmes carbocycliques
A61K 31/551 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p.ex. guanéthidine ou rifamycines ayant des cycles à sept chaînons, p.ex. azélastine, pentylènetétrazole ayant deux atomes d'azote comme hétéro-atomes d'un cycle, p.ex. clozapine, dilazèpe
A61P 29/00 - Agents analgésiques, antipyrétiques ou anti-inflammatoires non centraux, p.ex. agents antirhumatismaux; Médicaments anti-inflammatoires non stéroïdiens [AINS]
A61P 43/00 - Médicaments pour des utilisations spécifiques, non prévus dans les groupes
C07D 401/12 - Composés hétérocycliques contenant plusieurs hétérocycles comportant des atomes d'azote comme uniques hétéro-atomes du cycle, au moins un cycle étant un cycle à six chaînons avec un unique atome d'azote contenant deux hétérocycles liés par une chaîne contenant des hétéro-atomes comme chaînons
24.
DNA-BINDING PROTEIN USING PPR MOTIF, AND USE THEREOF
KYUSHU UNIVERSITY, NATIONAL UNIVERSITY CORPORATION (Japon)
HIROSHIMA UNIVERSITY (Japon)
Inventeur(s)
Yamamoto, Takashi
Sakuma, Tetsushi
Nakamura, Takahiro
Yagi, Yusuke
Okawa, Yasuyuki
Abrégé
[Problem] Based on the prediction that the rules for DNA recognition possessed by a PPR motif may also be used in DNA recognition, perform analysis of PPR protein that is active in DNA binding, and search for a PPR protein that has such characteristics. The present invention addresses the aforementioned problem by means of a protein that can bind DNA base-selectively or DNA base sequence-specifically, and that contains a plurality of, preferably 2-30, more preferably 5-25, and even more preferably 9-15, PPR motifs having the structure in formula 1 (in formula 1: Helix A is a part that can form an a helix structure; X is a part that does not exist or that comprises 1-9 amino acids; Helix B is a part that can form an a helix structure; and L is a part that comprises 2-7 amino acids), the PPR motif having a specific combination of three amino acids corresponding to the DNA base or target base sequence: first A.A. of Helix A and the 4th A.A. of Helix A in formula 1, together with the "ii"(-2)th A.A. contained in L. (Helix A)-X-(Helix B)-L (formula 1)
KYUSHU UNIVERSITY, NATIONAL UNIVERSITY CORPORATION (Japon)
SUMITOMO METAL MINING CO., LTD. (Japon)
Inventeur(s)
Goto, Masahiro
Kubota, Fukiko
Baba, Yuzo
Abrégé
The present invention extracts precious metals from an acidic solution containing precious metals in an early and highly efficient manner. Provided is an extraction agent for precious metals that is represented by the general formula below. In the formula, R1 and R2 each represent the same alkyl group or different alkyl groups, R3 represents a hydrogen atom or an alkyl group, and R4 represents a hydrogen atom or a discretionary group that is not an amino group and that bonds to a carbon as an amino acid. It is preferable that the general formula have a glycine unit, a histidine unit, a lysine unit, an aspartic acid unit, or an N-methylglycine unit (see above formula)
C22B 3/26 - Traitement ou purification de solutions, p.ex. de solutions obtenues par lixiviation par extraction liquide-liquide utilisant des composés organiques
KYUSHU UNIVERSITY, NATIONAL UNIVERSITY CORPORATION (Japon)
SUMITOMO METAL MINING CO., LTD. (Japon)
Inventeur(s)
Goto, Masahiro
Kubota, Fukiko
Baba, Yuzo
Abrégé
In order to selectively extract copper and/or lead from an acidic solution containing high concentrations of manganese, etc., the valuable-metal extracting agent of the present invention is expressed by general formula (1). In the formula, R1 and R2 each represent the same or different alkyl groups, R3 represents a hydrogen atom or an alkyl group, and R4 represents a hydrogen atom or a given group, other than an amino group, that bonds with an a carbon as an amino acid. In general formula (1), the inclusion of a glycine unit, a histidine unit, a lysine unit, an asparagine acid unit, or a normal methylglycine unit is preferred. When using the extracting agent to extract copper/and lead, it is preferable that the pH of the acidic solution be adjusted to 1.0-5.5 inclusive.
C22B 3/26 - Traitement ou purification de solutions, p.ex. de solutions obtenues par lixiviation par extraction liquide-liquide utilisant des composés organiques
KYUSHU UNIVERSITY, NATIONAL UNIVERSITY CORPORATION (Japon)
SUMITOMO METAL MINING CO., LTD. (Japon)
Inventeur(s)
Goto, Masahiro
Kubota, Fukiko
Baba, Yuzo
Ozaki, Yoshitomo
Hayata, Jiro
Higaki, Tatsuya
Nagakura, Toshihiko
Matsumoto, Shinya
Abrégé
Provided is a method for efficiently separating nickel, cobalt and/or scandium, and impurities from an acidic solution containing impurities such as manganese, iron, zinc, and aluminum. A valuable-metal extracting agent of the present invention is expressed by general formula (1). In the formula, R1 and R2 each represent the same or different alkyl groups, R3 represents a hydrogen atom or an alkyl group, and R4 represents a hydrogen atom or a given group, other than an amino group, that bonds with an a carbon as an amino acid. In general formula (1), the inclusion of a glycine unit, a histidine unit, a lysine unit, an asparagine acid unit, or a normal methylglycine unit is preferred. (see above formula)
C22B 3/26 - Traitement ou purification de solutions, p.ex. de solutions obtenues par lixiviation par extraction liquide-liquide utilisant des composés organiques
KYUSHU UNIVERSITY, NATIONAL UNIVERSITY CORPORATION (Japon)
SUMITOMO METAL MINING CO., LTD. (Japon)
Inventeur(s)
Goto, Masahiro
Kubota, Fukiko
Baba, Yuzo
Abrégé
In the present invention, nickel is selectively extracted from an acidic solution that contains a high concentration of manganese. This valuable metal extraction agent is represented by the general formula. In the formula, R1 and R2 are alkyl groups that may be the same or different, R3 is a hydrogen atom or an alkyl group, and R4 is a hydrogen atom or any group, other than an amino group, bonded to an a carbon atom of an amino acid. The general formula preferably has a glycine unit, a histidine unit, a lysine unit, an aspartic acid unit or a n-methylglycine unit. When extracting nickel by using this extraction agent, it is preferable to adjust the pH of the acidic solution to 2.3 to 5.5 inclusive.
C07C 237/06 - Amides d'acides carboxyliques, le squelette carboné de la partie acide étant substitué de plus par des groupes amino ayant les atomes de carbone des groupes carboxamide liés à des atomes de carbone acycliques du squelette carboné le squelette carboné étant acyclique et saturé ayant les atomes d'azote des groupes carboxamide liés à des atomes d'hydrogène ou à des atomes de carbone acycliques
C22B 3/26 - Traitement ou purification de solutions, p.ex. de solutions obtenues par lixiviation par extraction liquide-liquide utilisant des composés organiques
C22B 7/00 - Mise en œuvre de matériaux autres que des minerais, p.ex. des rognures, pour produire des métaux non ferreux ou leurs composés
H01M 10/54 - Récupération des parties utiles des accumulateurs usagés
29.
CARDIOVASCULAR DISEASE PRIMARY PREVENTION AGENT FOR PATIENTS HAVING HIGH BLOOD LEVELS OF HIGH-SENSITIVITY C-REACTIVE PROTEIN
KYUSHU UNIVERSITY, NATIONAL UNIVERSITY CORPORATION (Japon)
MOCHIDA PHARMACEUTICAL CO., LTD. (Japon)
Inventeur(s)
Kiyohara, Yutaka
Ninomiya, Toshiharu
Yano, Takashi
Abrégé
The present invention provides the following: a cardiovascular disease primary prevention agent, which comprises as the active ingredient at least one selected from the group consisting of EPA, salts thereof, and esters thereof and is for lowering the risk of cardiovascular disease by administration to subjects having a blood (serum or plasma) hs-CRP level of 1.0 mg/L or higher in spite of no history of cardiovascular disease; a combination marker comprising the blood hs-CRP value and serum EPA/AA ratio for evaluating the primary risk of cardiovascular disease in subjects having no history of cardiovascular disease; and a method for extracting subjects with high risk of cardiovascular disease and/or a method for preventing cardiovascular disease.
A61K 31/202 - Acides carboxyliques, p.ex. acide valproïque ayant un groupe carboxyle lié à une chaîne acyclique d'au moins sept atomes de carbone, p.ex. acides stéarique, palmitique ou arachidique ayant au moins trois doubles liaisons, p.ex. acide linolénique
A61K 31/232 - Esters, p.ex. nitroglycérine, sélénocyanates d'acides carboxyliques d'acides acycliques, p.ex. pravastatine d'acides ayant un groupe carboxyle lié à une chaîne d'au moins sept atomes de carbone ayant au moins trois doubles liaisons, p.ex. étrétinate
A61P 7/12 - Antidiurétiques, p.ex. médicaments pour le traitement du diabète insipide
A61P 9/00 - Médicaments pour le traitement des troubles du système cardiovasculaire
A61P 9/10 - Médicaments pour le traitement des troubles du système cardiovasculaire des maladies ischémiques ou athéroscléreuses, p.ex. médicaments antiangineux, vasodilatateurs coronariens, médicaments pour le traitement de l'infarctus du myocarde, de la rétinopathie, de l'insuffisance cérébro-vasculaire, de l'artériosclérose rénal
G01N 30/88 - Systèmes intégrés d'analyse, spécialement adaptés à cet effet, non couverts par un seul des groupes
G01N 33/50 - Analyse chimique de matériau biologique, p.ex. de sang ou d'urine; Test par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligands; Test immunologique
G01N 33/53 - Tests immunologiques; Tests faisant intervenir la formation de liaisons biospécifiques; Matériaux à cet effet
KYUSHU UNIVERSITY, NATIONAL UNIVERSITY CORPORATION (Japon)
SUMITOMO METAL MINING CO., LTD. (Japon)
Inventeur(s)
Goto, Masahiro
Kubota, Fukiko
Baba, Yuzo
Abrégé
The objective of the present invention is to selectively extract cobalt from an acidic solution containing a high concentration of manganese. This cobalt extraction method extracts cobalt from an acidic solution containing manganese and cobalt by subjecting the acidic solution to solvent extraction by means of a valuable metal extraction agent comprising an amide derivative represented by general formula (I). The valuable metal extraction agent is represented by the general formula. In the formula: R1 and R2 each represent the same or different alkyl group; R3 represents a hydrogen atom or an alkyl group; and R4 represents a hydrogen atom or any given group aside from an amino group bonded to the a carbon as an amino acid. Preferably, the general formula has a glycine unit, a histidine unit, a lysine unit, an aspartic acid unit, or an N-methylglycine unit. Preferably, the pH of the acidic solution is 3.5-5.5 inclusive.
KYUSHU UNIVERSITY, NATIONAL UNIVERSITY CORPORATION (Japon)
SUMITOMO METAL MINING CO., LTD. (Japon)
Inventeur(s)
Goto, Masahiro
Kubota, Fukiko
Baba, Yuzo
Abrégé
The objective of the present invention is to selectively extract light rare earth metals, and by extension, europium, from an acidic solution containing a plurality of types of rare earth metal. This valuable metal extraction agent is represented by the general formula. In the formula: R1 and R2 each indicate the same or different alkyl group; R3 indicates a hydrogen atom or an alkyl group; and R4 indicates a hydrogen atom or any given group other than an amino group bonded to the a carbon as an amino acid. Preferably, the general formula has a glycine unit, a histidine unit, a lysine unit, an aspartic acid unit, or an N-methylglycine unit. Preferably, when extracting europium using the extraction agent, the pH is adjusted into the range of 2.0-3.0 inclusive, and when selectively extracting light rare earth metals, the pH is adjusted to 1.7-2.7 inclusive. (see above formula)
A P2X4 receptor antagonist such as paroxetine, a diazepinedione derivative having the following formula (IX) is used as an agent for preventing or treating neuropathic pain associated with Guillain-Barre syndrome: wherein R1 is hydrogen, a C1-8 alkyl group, or the like; each of R2 and R3 is hydrogen, a C1-8 alkyl group, or the like; each of R4 and R5 is hydrogen or the like; and W is a five-membered or six-membered heterocyclic ring optionally having one or more substituents and comprising one to four nitrogen atoms as the members of the ring. (see above formula)
A61K 31/551 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p.ex. guanéthidine ou rifamycines ayant des cycles à sept chaînons, p.ex. azélastine, pentylènetétrazole ayant deux atomes d'azote comme hétéro-atomes d'un cycle, p.ex. clozapine, dilazèpe
A P2X4 receptor antagonist such as paroxetine, a di- azepinedione derivative having the following formula (IX) is used as an agent for preventing or treating zoster- associated pain in acute phase: wherein R1 is hydrogen, a C1-8 alkyl group, or the like; each of R2 and R3 is hydrogen, a C1-8 alkyl group, or the like; each of R4 and R5 is hydrogen or the like; and W is a five-membered or six-membered heterocyclic ring optionally having one or more substituents and comprising one to four nitrogen atoms as the members of the ring.
A61K 31/551 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p.ex. guanéthidine ou rifamycines ayant des cycles à sept chaînons, p.ex. azélastine, pentylènetétrazole ayant deux atomes d'azote comme hétéro-atomes d'un cycle, p.ex. clozapine, dilazèpe
A61K 31/445 - Pipéridines non condensées, p.ex. pipérocaïne
A61P 25/02 - Médicaments pour le traitement des troubles du système nerveux des neuropathies périphériques
A61P 29/00 - Agents analgésiques, antipyrétiques ou anti-inflammatoires non centraux, p.ex. agents antirhumatismaux; Médicaments anti-inflammatoires non stéroïdiens [AINS]
34.
TRANSFORMATION OF A STRAMENOPILE FOR PRODUCTION OF A MICROBIAL OIL
KYUSHU UNIVERSITY, NATIONAL UNIVERSITY CORPORATION (Japon)
UNIVERSITY OF MIYAZAKI (Japon)
KONAN GAKUEN (Japon)
NIPPON SUISAN KAISHA, LTD. (Japon)
Inventeur(s)
Sakaguchi, Keishi
Hamaguchi, Rie
Matsuda, Takanori
Ito, Makoto
Nagano, Naoki
Hayashi, Masahiro
Honda, Daisuke
Okita, Yuji
Sugimoto, Shinichi
Abrégé
[Problem] To provide a transformation method for producing a stramenopile organism having an improved unsaturated fatty acid production capability by disrupting a gene of the stramenopile organism or inhibiting the expression of the gene in a genetically engineering manner. [Solution] A method for transforming a stramenopile organism, which comprises disrupting a gene of the stramenopile organism or inhibiting the expression of the gene in a genetically engineering manner, and which is characterized in that the stramenopile organism is selected from Thraustochytrium aureum, Parietichytrium sarkarianum, Thraustochytrium roseum and Parietichytrium sp. and the gene to be disrupted or of which the expression is to be inhibited is a gene associated with the biosynthesis of a fatty acid.
C12N 1/15 - Champignons; Leurs milieux de culture modifiés par l'introduction de matériel génétique étranger
C12N 1/13 - Algues unicellulaires; Leurs milieux de culture modifiés par l'introduction de matériel génétique étranger
C12N 15/52 - Gènes codant pour des enzymes ou des proenzymes
C12P 7/64 - Graisses; Huiles; Cires de type ester; Acides gras supérieurs, c. à d. ayant une chaîne continue d'au moins sept atomes de carbone liée à un groupe carboxyle; Huiles ou graisses oxydées
A method of detecting space debris includes generating a virtual space debris piece in accordance with the law of conservation of mass by applying a debris breakup model to an object of breakup origin which is likely to have broken up on a geocentric orbit in the past (steps 1 and 3) , calculating an orbit of each virtual space debris piece during fixed point observation by applying a debris orbit propagation model to the virtual space debris piece (step 55) , and generating appearance frequency distribution of a motion vector of each virtual space debris piece on the celestial sphere on the basis of a result of the orbit calculation (step S13) . The series of the above steps are executed multiple times (step S9, step S11) . The method further includes setting a search range vector on the basis of a motion vector having a high level of the appearance frequency distribution. of the motion vector, and applying a stacking method to regions in images captured at time intervals during the fixed point observation, the regions being shifted along the search range vector sequentially in the order of capture, thereby detecting space debris appearing on the images (steps S17 to S21).
KYUSHU UNIVERSITY, NATIONAL UNIVERSITY CORPORATION (Japon)
KYOWA KIRIN CO., LTD. (Japon)
Inventeur(s)
Takayanagi, Shin-Ichiro
Tomura, Hitomi
Tawara, Tomonori
Inagaki, Yoshimasa
Kubota, Tsuguo
Akashi, Koichi
Kikushige, Yoshikane
Abrégé
The present invention provides an anti-human TIM-3 antibody which binds to the amino acid sequence of the extracellular region of TIM-3 or its three- dimensional structure thereof and exhibits higher effector activity such as an antibody- dependent cellular cytotoxicity (ADCC activity) for diseases relating to a human TIM-3 expressing cell. The present invention provides a monoclonal antibody or antibody fragment thereof which binds to the amino acid sequence of the extracellular region of TIM-3 or its three-dimensional structure and exhibits ADCC activity; a hybridoma which produces the antibody; a DNA encoding the antibody; a vector comprising the DNA; a transformant which is obtainable by introducing the vector; a method for producing the antibody or the antibody fragment thereof which comprises using the hybridoma or the transformant; a therapeutic agent and a diagnostic agent comprising the antibody or the antibody fragment thereof as an active ingredient. In addition, the present invention provides an anti-human TIM-3 antibody having high ADCC activity by screening an anti-human TIM-3 antibody which competes with the monoclonal antibody or the antibody fragment thereof.
C07K 16/28 - Immunoglobulines, p.ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire
G01N 33/577 - Tests immunologiques; Tests faisant intervenir la formation de liaisons biospécifiques; Matériaux à cet effet faisant intervenir des anticorps monoclonaux
KYUSHU UNIVERSITY, NATIONAL UNIVERSITY CORPORATION (Japon)
UNIVERSITY OF MIYAZAKI (Japon)
KONAN GAKUEN (Japon)
NIPPON SUISAN KAISHA, LTD. (Japon)
Inventeur(s)
Sakaguchi, Keishi
Kobayashi, Takumi
Ito, Makoto
Nagano, Naoki
Hayashi, Masahiro
Honda, Daisuke
Taoka, Yosuke
Okita, Yuji
Izumida, Hitoshi
Sugimoto, Shinichi
Matsuda, Takanori
Abrégé
Disclosed is a transformation method whereby an ability to produce a useful substance of a stramenopile can be improved. The method for transforming a stramenopile comprises transferring a foreign gene into the stramenopile which is a microorganism belonging to the class Labyrinthula, more specifically, to a genus Labyrinthula, Altornia, Aplanochytrium, Schizochytrium, Aurantiochytrium, Thraustochytrium, Ulkenia, etc. Said foreign gene, which is a gene relating to tolerance against an antibiotic, a colorimetric protein and/or a fatty acid desaturase (?5 desaturase gene, ?12 desaturase gene and/or ?3 desaturase gene), is transferred by using the electroporation or gene-gun technique.
A23D 9/00 - Autres huiles ou graisses comestibles, p.ex. huiles pour cuisson
A61K 31/202 - Acides carboxyliques, p.ex. acide valproïque ayant un groupe carboxyle lié à une chaîne acyclique d'au moins sept atomes de carbone, p.ex. acides stéarique, palmitique ou arachidique ayant au moins trois doubles liaisons, p.ex. acide linolénique
A61K 35/66 - Micro-organismes ou substances provenant de micro-organismes
C11B 1/00 - Production des graisses ou huiles à partir de matières premières
C11C 3/00 - Graisses, huiles ou acides gras obtenus par transformation chimique des graisses, huiles ou acides gras, p.ex. ozonolyse
C12N 1/00 - Micro-organismes, p.ex. protozoaires; Compositions les contenant; Procédés de culture ou de conservation de micro-organismes, ou de compositions les contenant; Procédés de préparation ou d'isolement d'une composition contenant un micro-organisme; Leurs milieux de culture
C12N 1/11 - Protozoaires; Leurs milieux de culture modifiés par l'introduction de matériel génétique étranger
C12N 1/13 - Algues unicellulaires; Leurs milieux de culture modifiés par l'introduction de matériel génétique étranger
KYUSHU UNIVERSITY, NATIONAL UNIVERSITY CORPORATION (Japon)
Inventeur(s)
Okada, Shigeto
Yamaki, Jun-Ichi
Waseda, Tetsuya
Isono, Motoshi
Abrégé
Electrode active material that is used together with an electrolyte solution having an electrolyte decomposition potential Ve is represented by the general expression LixFeMyO2 and is amorphous. In the expression, x and y are values which independently satisfy 1 < x <= 2.5 and O < y <= 3, respectively, and z = (x + (valence of Fe) + (valence of M) x y) / 2 to satisfy stoichiometry, and M represents one or two or more types of glass former element. The average electronegativity of M is less than (Ve + 6.74 / 5.41.
H01M 4/36 - Emploi de substances spécifiées comme matériaux actifs, masses actives, liquides actifs
39.
POSITIVE ELECTRODE ACTIVE MATERIAL AND METHOD OF PRODUCING THE SAME AND NONAQUEOUS ELECTROLYTE BATTERY HAVING POSITIVE ELECTRODE CONTAINING POSITIVE ELECTRODE ACTIVE MATERIAL
KYUSHU UNIVERSITY, NATIONAL UNIVERSITY CORPORATION (Japon)
Inventeur(s)
Iizuka, Shinji
Omae, Osamu
Sueto, Kumiko
Shimada, Takeshi
Okada, Shigeto
Iwanaga, Tomoko
Shiratsuchi, Tomoyuki
Yamaki, Jun-Ichi
Abrégé
There are provided positive electrode active materials that consist essentially of an olivine-type lithium manganese phosphate compound particles represented by the following general formula (2) Li x Mn y M1z M2 w PO4 (2) wherein 0 < x < 2, 0 < y < 1, 0 < z < 0.2, 0 < w < 0.2, M1 is at least one divalent metal element selected from the group consisting of Co, Ni, and Fe, and M2 is Ti; and carbon on the surface of the olivine-type lithium manganese phosphate compound particles in an amount no greater than 20 weight% wherein said positive electrode active material has a particle diameter of 10 to 500 nm. There are also provided methods of producing such positive electrode active materials.
H01M 4/58 - Emploi de substances spécifiées comme matériaux actifs, masses actives, liquides actifs de structures polyanioniques, p.ex. phosphates, silicates ou borates
H01M 4/136 - PROCÉDÉS OU MOYENS POUR LA CONVERSION DIRECTE DE L'ÉNERGIE CHIMIQUE EN ÉNERGIE ÉLECTRIQUE, p.ex. BATTERIES Électrodes Électrodes composées d'un ou comprenant un matériau actif Électrodes pour accumulateurs à électrolyte non aqueux, p.ex. pour accumulateurs au lithium; Leurs procédés de fabrication Électrodes à base de composés inorganiques autres que les oxydes ou les hydroxydes, p.ex. sulfures, séléniures, tellurures, halogénures ou LiCoFy
H01M 4/1397 - Procédés de fabrication d’électrodes à base de composés inorganiques autres que les oxydes ou les hydroxydes, p.ex. sulfures, séléniures, tellurures, halogénures ou LiCoFy
H01M 10/0585 - Structure ou fabrication d'accumulateurs ayant uniquement des éléments de structure plats, c. à d. des électrodes positives plates, des électrodes négatives plates et des séparateurs plats
C01B 25/45 - Phosphates contenant plusieurs métaux ou un métal et l'ammonium
KYUSHU UNIVERSITY, NATIONAL UNIVERSITY CORPORATION (Japon)
Inventeur(s)
Okada, Shigeto
Shiratsuchi, Tomoyuki
Iwanaga, Tomoko
Yamaki, Jun-Ichi
Iizuka, Shinji
Omae, Osamu
Sueto, Kumiko
Shimada, Takeshi
Abrégé
The present invention provides a positive electrode active material that has rate characteristics suitable for nonaqueous electrolyte batteries and particularly nonaqueous electrolyte secondary batteries, a method by which this positive electrode active material can be easily mass produced, and a high-performance nonaqueous electrolyte battery that has a positive electrode active material obtained by this method. The present invention relates to a method of producing a positive electrode active material, the method comprising a step of mixing a carbon source with lithium manganese phosphate LiMnPO4 or a compound LiMn1-x M x PO4 (where, 0 <= x < 1 and M is at least one metal element selected from the group consisting of Co, Ni, Fe, Zn, Cu, Ti, Sn, Zr, V, and Al) containing lithium manganese phosphate LiMnPO4 as a solid solution composition, and heat treating the obtained mixture under an inert gas atmosphere.
H01M 4/1397 - Procédés de fabrication d’électrodes à base de composés inorganiques autres que les oxydes ou les hydroxydes, p.ex. sulfures, séléniures, tellurures, halogénures ou LiCoFy
H01M 10/0585 - Structure ou fabrication d'accumulateurs ayant uniquement des éléments de structure plats, c. à d. des électrodes positives plates, des électrodes négatives plates et des séparateurs plats
41.
BONE SUBSTITUTE MATERIAL FOR MEDICAL USE AND METHOD FOR PRODUCING THE SAME
KYUSHU UNIVERSITY, NATIONAL UNIVERSITY CORPORATION (Japon)
Inventeur(s)
Ishikawa, Kunio
Matsuya, Shigeki
Nakagawa, Masaharu
Udou, Kouichi
Abrégé
There is disclosed a bone substitute material for medical use which satisfies all the requirements of (1) no histotoxicity, (2) osteoconductivity, (3) bone replacement capability, and (4) mechanical strength necessary for a bone reconstruction operation. The bone substitute material for medical use is predominantly composed of carbonate apatite and produced through the formation of carbonate apatite by contacting a block of calcium compound with a phosphate-containing solution, wherein the calcium compound block contains substantially no powders, and at least one of said calcium compound block and said phosphate solution contains a carbonate group, without any sintering. The block of calcium compound is preferably one prepared using an artificially synthesized calcium compound, most preferably a foamed calcium compound.